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ABSTRACT
Gulf War Illness (GWI) is a chronic multi-symptom disorder afflicting the veterans of the First Gulf War, and includes
neurological symptoms characterized by depression and memory deficits. Chronic exposure to organophosphates (OPs) is
considered a leading cause for GWI, yet its pathobiology is not fully understood. We recently observed chronic elevations in
neuronal Ca2þ levels ([Ca2þ]i) in an OP-diisopropyl fluorophosphate (DFP)-based rat model for GWI. This study was aimed at
identifying mechanisms underlying elevated [Ca2þ]i in this DFP model and investigating whether their therapeutic targeting
could improve GWI-like neurological morbidities. Male Sprague-Dawley rats (9 weeks) were exposed to DFP (0.5 mg/kg, s.c.,
1-daily for 5 days) and at 3 months postDFP exposure, behavior was assessed and rats were euthanized for protein
estimations and ratiometric Fura-2 [Ca2þ]i estimations in acutely dissociated hippocampal neurons. In DFP rats, a sustained
elevation in intracellular Ca2þ levels occurred, and pharmacological blockade of Ca2þ-induced Ca2þ-release mechanisms
significantly lowered elevated [Ca2þ]i in DFP neurons. Significant reductions in the protein levels of the ryanodine receptor
(RyR) stabilizing protein Calstabin2 were also noted. Such a posttranslational modification would render RyR “leaky”
resulting in sustained DFP [Ca2þ]i elevations. Antagonism of RyR with levetiracetam significantly lower elevated [Ca
2þ]i in
DFP neurons and improved GWI-like behavioral symptoms. Since Ca2þ is a major second messenger molecule, such chronic
increases in its levels could underlie pathological synaptic plasticity that expresses itself as GWI morbidities. Our studies
show that treatment with drugs targeted at blocking intracellular Ca2þ release could be effective therapies for GWI
neurological morbidities.
Key words: organophosphates; DFP; depression; anxiety; memory deficits; levetiracetam; calcium dynamics; Sprague-Dawley
rats.
Approximately one-third of the deployed First Gulf War soldier
population suffer from a debilitating disorder called Chronic
Multi-Symptom Illness, popularly known as the Gulf War
Illness (GWI) (Gulf War and Health 2016; White et al., 2016).This
disorder continues to affect our Veterans 25 years after the War.
The Institute of Medicine defines GWI as a spectrum disorder
characterized by the presence of at least 2 of the following 6
categories of symptoms in the absence of other underlying dis-
orders, in soldiers deployed during the First Gulf War, for a pe-
riod of at least 6 months: fatigue, mood and cognitive changes,
pain, gastrointestinal symptoms, respiratory difficulty, and
neurologic abnormalities (Gulf War and Health, 2016). Thus,
GWI is a multi-symptom condition that has multi-system ori-
gins with the nervous system being particularly affected. GWI
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neurological impairments commonly include mood disorder,
anxiety, chronic depression, and cognitive deficits (Black et al.,
2004; Blore et al., 2015). These neuropsychiatric conditions are
particularly difficult to treat and significantly lower the quality
of life in GWI Veterans (Yee et al., 2016).
Deployment complexities of military personnel and their ex-
posure to multiple chemicals present in the First Gulf War the-
ater have made it difficult to identify the underlying etiology of
GWI (Brimfield, 2012). Amongst numerous purported causative
factors, it is now believed that chronic exposures to organo-
phosphate (OP) compounds, including pesticides such as chlor-
pyrifos and malathion, and accidental exposure to OP nerve
agents sarin and cyclosarin possibly underlies the development
of this disorder (Chao et al., 2015; Kerr, 2015; Tuite and Haley,
2013; White et al., 2016). Investigators have mimicked these ex-
posure conditions to develop rodent models of GWI (Abdel-
Rahman et al., 2004; Abdullah et al., 2013; Hernandez et al., 2015;
O’Callaghan et al., 2015; Parihar et al., 2013). One such model
uses Diisopropyl fluorophosphate (DFP), an OP compound,
which is used experimentally to mimic effects of the nerve
agent sarin (Deshpande et al., 2010). We previously developed a
model for GWI by exposing rats to repeated, low-dose DFP and
observed delayed neuronal injury and chronic neurobehavioral
morbidities including depression, anxiety, and cognitive deficits
similar to those reported in GWI Veterans, in the absence of
other deployment related confounding factors (Phillips and
Deshpande, 2016).
Calcium ions (Ca2þ) are signaling molecules that modulate
memory, mood, and behavior functions (Bengtson and Bading,
2012). Neuronal Ca2þ homeostasis is a tightly controlled process
involving a complex interplay between influx, efflux, release,
and buffering mechanisms within the cytoplasm. Ca2þ-induced
Ca2þ-release (CICR) is one such process that is mediated by rya-
nodine receptors (RyRs) and inositol tris-phosphate receptors
(IP3R) that amplify Ca
2þ signal by releasing additional Ca2þ from
the endoplasmic reticulum (ER) in response to Ca2þ influx via
plasmalemmal channels. Disruptions in neuronal Ca2þ homeo-
stasis are implicated in many neurodegenerative disorders in-
cluding Alzheimer’s disease (Popugaeva et al., 2017), Parkinson’s
disease (Surmeier et al., 2017), acquired epilepsy (Nagarkatti
et al., 2009), and traumatic brain injury (TBI) (Tehse and
Taghibiglou, 2018). These disorders manifest psychiatric comor-
bidities like those seen in GWI Veterans. In line with these
observations, we recently reported that repeated, low-dose DFP-
exposed rats exhibited significantly higher hippocampal Ca2þ
levels than their age-matched counterparts (Phillips and
Deshpande, 2018). However, the mechanisms underlying these
sustained neuronal Ca2þ elevations in GWI are unknown. In this
study, we investigated a molecular basis for the development of
GWI-like neurological morbidities in our DFP-based rodent
model. We further investigated whether pharmacological inhi-
bition of CICR-mediated Ca2þ elevations could also prove to be
an effective therapy for GWI-like neurological conditions.
MATERIALS ANDMETHODS
Animals
All animal use procedures were in strict accordance with the
National Institute of Health Guide for the Care and Use of
Laboratory Animals. The experimental protocol was approved
by Virginia Commonwealth University’s Institutional Animal
Care and Use Committee and by the Animal Care and Use
Review Office of the U.S. Army Medical Research and Material
Command. Male Sprague-Dawley rats (Envigo, Indianapolis,
Indiana) weighing approximately 300 g and 9 weeks of age were
used in this study. Animals were housed 2 per cage at 20C–
22C with a 12-h light-dark cycle (lights on 06:00–18:00 h) and
given free access to food and water.
Chemicals
All the chemicals were obtained from Sigma Aldrich Company
(St Louis, Missouri) unless otherwise noted. Levetiracetam (LEV,
Keppra) in injectable form was obtained from VCU Division of
Animal Resources Pharmacy. Drugs and buffer solutions were
made fresh daily.
DFP Exposure
Immediately upon arrival, DFP (Catalog no. D-0879) was
inspected for discoloration that would indicate possible degra-
dation due to oxidation. The vial containing colorless DFP was
stored at 80C. DFP has a short half-life (1 h, pH 7.5 at 25C). On
the day of the prep, DFP was removed from the vial using a
Hamilton syringe and diluted with ice-cold phosphate buffered
saline to a concentration of 0.5 mg/ml. Syringes filled with DFP
were kept on ice and rats were injected with DFP or vehicle
within 15 min of DFP preparation.
Rats were injected with DFP (0.5 mg/kg, s.c.) once daily for 5
days, while control rats received DFP vehicle injections for the
same period. DFP was injected subcutaneously on the back of
the rat with a volume ranging between 0.3 and 0.32 ml. Animal
health including weight measurements were assessed daily
during the exposure and for an additional 7 days following DFP
injections. A small percentage of DFP injected rats (<5%) exhib-
ited mild tremors around the fifth day of dosing that resolved
within 24 h without the need of any pharmacological interven-
tion. DFP-exposed rats showed no observable seizures or other
hyper-cholinergic activity.
Experimental Design
At 3 months following DFP exposures, no significant differences
in weights were observed between control and DFP exposed
rats. At this time point postDFP exposure, rats were separated
into 4 groups: group I: neuronal ratiometric intracellular Ca2þ
measurements and group II: Western blot analysis. Groups III
and IV rats were administered LEV (50 mg/kg, i.p.) twice daily
for 4 days followed by behavioral analysis or ratiometric Ca2þ
measurement on the fifth day (Figure 1). Age-matched control
rats also received LEV injections and were subjected to behav-
ioral analysis.
Assessment of Depression and Memory
Symptoms of depression and memory deficit were carried out
using tests described below. Testing was carried out between
09:00 and 15:00 h. Normal lighting in the testing room was ap-
proximately 600 lux. For behavioral testing, the lighting was ad-
justed to a dimmer setting of approximately 300 lux. For
elevated plus maze (EPM), open arm light levels were approxi-
mately 200 lux and closed arm light levels were approximately
150 lux. All light was reflected off photography-grade white
shades and did not directly shine on the testing apparatus. The
room was not sound-proof, but the interior location ensured
that it remained quiet during behavioral assessments.
Reviewers were blinded to treatment conditions.
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Sucrose preference test
This test measures hedonia (pleasure-seeking) or lack of it (an-
hedonia) by monitoring a rat’s preference to sucrose-laced wa-
ter (Deshpande et al., 2014; Forbes et al., 1996; Overstreet, 2012;
Phillips and Deshpande, 2016). Briefly, rats were habituated to
having 2 bottles in the cage lid for 4 days. The bottles were fitted
with ball-bearing sipper tubes that prevented fluids from leak-
ing. Water intake was measured daily to ascertain that rats
were progressively showing lesser side-bias. Following this ac-
climation, on the fifth day, rats were deprived of water but not
food overnight for a total of 19 h. On the sixth day, 2 bottles
were again introduced in the cage-top. Rats had the free choice
of either drinking a 1% sucrose solution or plain water for a total
period of 1 h. After 30 min, positions of water and sucrose bot-
tles were swapped to further control for any confounding
effects produced by a side bias. Both the volume of fluid and
weight of the bottle were measured before and after the test.
Sucrose preference was calculated as a percentage of the su-
crose intake over the total fluid intake. A spill-cage without rat
was also employed using bottles and sipper tubes from the
same batch as test cages. Measurement errors were 6 2 ml.
Forced swim test
Porsolt’s modified forced swim test (FST) was used to assess be-
havioral despair (Castagne et al., 2011; Deshpande et al., 2014;
Overstreet, 2012; Phillips and Deshpande, 2016). Briefly, animals
were placed in a glass cylindrical chamber (46-cm height  30-
cm depth) filled with water (30-cm height, 25C) forced to swim
for 6 min. Swimming sessions were recorded for off-line analy-
sis. Active (swimming, climbing, and diving) and passive (im-
mobility) behavior was evaluated by 2 reviewers blinded to the
treatment conditions. Immobility (primary outcome) was
defined as the period during which the animal floats in the wa-
ter making only those movements necessary to keep its head
above water. The tank was emptied and thoroughly cleaned for
every rat to be tested in a session.
Elevated plus maze
This test assesses anxiety by considering the innate behavior of
rats to prefer dark enclosed spaces over bright open spaces
(Deshpande et al., 2014; Phillips and Deshpande, 2016; Walf and
Frye, 2007). By using rodents’ proclivity toward dark, enclosed
spaces (approach) and an unconditioned fear of heights/open
spaces (avoidance), EPM allows for the measurement of anxiety
state in the absence of noxious stimuli that typically produce a
conditioned response (Walf and Frye, 2007). The maze (Med
Associates Inc., St Albans, Vermont) was made of black polyvi-
nyl chloride and consisted of 4 arms, 50-cm long  10-cm wide,
connected by a central square, 10  10 cm: 2 open without walls
and 2 closed by 31-cm high walls. All arms were attached to
sturdy metal legs; the maze was elevated 55 cm above the floor
level and was set in a dimly lit room. A video camera was sus-
pended above the maze to record the rat movements for analy-
sis. A video-tracking system (Noldus Ethovision XT 11) was used
to automatically collect behavioral data. The procedure con-
sisted of placing the rats at the junction of the open and closed
arms, the center of the maze, facing the open arm opposite to
where the experimenter was. The video-tracking system was
started after the animal was placed in the maze so that the be-
havior of each animal was consistently recorded for 5 min. At
the end of the 5-min test session, the rat was removed from the
plus maze and returned to its home cage. The maze was
cleaned with 70% ethanol and air-dried to remove any scent
traces and allowed to dry completely before introducing the
Figure 1. Timeline of experimental studies. Nine-week-old male Sprague-Dawley rats (n ¼ 45) were exposed once daily to OP agent DFP (0.5 mg/kg, s.c.). Three months
later, DFP rats and age-matched vehicle control rats were divided in 4 groups. Group 1 DFP rats were euthanized, CA1 hippocampal neurons acutely isolated and imme-
diately subjected to Ca2þ imaging studies including basal Ca2þ measurements and in vitro antagonist studies. Group 2 DFP rats were euthanized, hippocampal homo-
genates obtained and subjected to Western blot analysis. Group 3 DFP rats received either LEV (50 mg/kg, i.p.) or saline twice daily for 4 days. Age-matched control rats
also received similar treatments. On the fifth day, these rats were subjected to behavioral tests to assess for the symptoms of depression, anxiety, and memory func-
tion. Group 4 DFP and control rats received similar treatments as group 3 but were subjected to Ca2þ imaging.
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next animal in the arena. Time spent and entries made in the
various arms of EPM were calculated.
Novel object recognition test
This test assesses object recognition memory by calculating the
preference of the rat to explore a novel object (Bevins and
Besheer, 2006; Deshpande et al., 2014; Phillips and Deshpande,
2016). Briefly, rats were placed in black Perspex box 90  60  50
cm in a dimly illuminated and quiet animal behavior testing
room. Rats were habituated individually, by allowing them to
explore the empty box for 10 min per session for 2 days. The
arena was cleaned with a 70% ethanol solution and dried
completely in between each subject so as to eliminate any po-
tential odor cues left by previous subjects. On the third day, in
the sample phase, 2 identical objects (A, A) were placed in oppo-
site corners of the box, 20 cm from the wall. A rat was allowed
to explore for 3 min, and then it was removed from the box and
returned to its home cage. In the choice phase (1 h later), one of
the objects was replaced with a novel object (B), and the rat was
allowed to explore for 2 min. Objects were similar in size and
emotionally neutral. A video-tracking system (Noldus
Ethovision XT 11) was used to automatically collect behavioral
data. Direct contacts included any contact with mouth, nose or
paw and did not include contacts that were accidental (backing
or bumping into the object). Also, standing, sitting or leaning on
the object was not scored as object interaction. A rat is exploring
an object when its nose is within 2 cm of the object. Frequency
and time spent exploring the new object (B) versus the familiar
object (A) was calculated for each group.
Isolation of Hippocampal CA1 Neurons and Loading
With Fura-2
Acute isolation of CA1 hippocampal neurons was performed by
established procedures routinely used in our laboratory
(Deshpande et al., 2010; Phillips and Deshpande, 2018; Raza
et al., 2004). Animals were anesthetized with isoflurane and de-
capitated. Brains were rapidly dissected and placed in 4C oxy-
genated (95% O2/5% CO2) artificial cerebrospinal fluid (aCSF)
consisting of (in mM): 201.5 sucrose, 10 glucose, 1.25 NaH2PO4,
26 NaHCO3, 3 KCl, 7 MgCl2, and 0.2 CaCl2). MK-801 (1 lM) was
added to all solutions to increase cell viability and was removed
15 min prior to imaging. Hippocampal slices (450 lm) were cut
on a vibrating microtome (Leica Microsystems, Wetzlar,
Germany) and then equilibrated for 10 min at 34C in a
piperazine-N, N’-bis[2-ethanesulfonic acid] (PIPES)-aCSF solu-
tion containing (in mM): 120 NaCl, 25 glucose, 20 PIPES, 5 KCl, 7
MgCl2, and 0.1 CaCl2. Slices were then treated with 8 mg/ml pro-
tease in PIPES-aCSF for 6 min at 34C and rinsed. Enzyme-
treated slices were visualized on a dissecting microscope to
excise the CA1 hippocampal region which was then triturated
with a series of Pasteur pipettes of decreasing diameter in cold
(4C) PIPES-aCSF solution containing 1 lM Fura-2 AM
(Invitrogen, Carlsbad, California). The cell suspension was
placed in the middle of 2-well glass-bottom chambers (Nunc,
Thermo Scientific). These glass chambers were previously
treated overnight with 0.05 mg/ml poly-L-lysine followed by
multiple rinses with distilled water and then further treated
with Cell-Tak (BD-Biosciences, San Jose, California) biocompati-
ble cellular adhesive (3.5 lg/cm2) for 30 min, rinsed and air-
dried. Neuronal suspension placed in the center of adhesive
coated dishes when settled firmly adhered to the bottom. This
technique simplified further manipulations on the dissociated
neurons. Plates were then incubated at 37C in a 5% CO2/95% air
atmosphere for 45 min. Fura-2 was washed off with PIPES-aCSF
containing no MK-801 and plates were incubated an additional
15 min to allow for complete cleavage of the AM moiety from
Fura-2.
Measurement of [Ca21]i
Fura-2 loaded cells were transferred to a 37C heated stage
(Harvard Apparatus, Hollington, Massachusetts) on an Olympus
IX-70 inverted microscope coupled to a fluorescence imaging
system (Olympus America, Center Valley, Pennsylvania) and
subjected to [Ca2þ]i measurements by procedures well estab-
lished in our laboratory (Deshpande et al., 2010; Phillips and
Deshpande, 2018; Raza et al., 2004). All experiments were per-
formed using a 20, 0.7 N.A. water immersion objective and
images were recorded by an ORCA-ER high-speed digital CCD
camera (Hammamatsu Photonics K.K., Japan). Fura-2 was ex-
cited with a 75 W xenon arc lamp (Olympus America). Ratio
images were acquired by alternating excitation wavelengths
(340/380 nm) by using a Lambda 10-2 filter wheel (Sutter
Instruments Co., Novato, California) and a Fura filter cube at
510/540 emission with a dichroic at 400 nm. All image acquisi-
tion and processing was controlled by a computer connected to
the camera and filter wheel using Metafluor Software ver 7.6
(MDS Analytical Technologies, Downington, Pennsylvania).
Image pairs were captured every 5 s and the images at each
wavelength were averaged over 10 frames. Background fluores-
cence was obtained by imaging a field lacking Fura-2.
Hippocampal CA1 neurons were identified based on their dis-
tinct morphology. These neurons displayed pyramidal shaped
cell body, long axon and dendrites and have been demonstrated
to be devoid of immunoreactivity for specific protein markers
for interneurons, including parvalbumin, cholecystokinin, vaso-
active intestinal peptide, somatostatin, and neuropeptide Y
(Deshpande et al., 2010; Phillips and Deshpande, 2018; Raza
et al., 2004). The process of enzymatic treatment and mechani-
cal trituration can add minimal stress during acute dissociation
of neurons. However, we have shown previously that the neu-
rons isolated using these procedures exhibit electrophysiologi-
cal properties identical to neurons in slices or in cultures, are
viable, and not apoptotic or necrotic (Sun et al., 2008).
Calcium Calibration
We performed Ca2þ calibration determinations as described
previously (Deshpande et al., 2010; Phillips and Deshpande,
2018; Raza et al., 2004) to provide estimates of absolute [Ca2þ]i
concentrations from the 340/380 ratio values. A Ca2þ calibration
curve was constructed using solutions of calibrated Ca2þ buffers
ranging from 0 Ca2þ (Ca2þ free) to 39 lM Ca2þ (Invitrogen).
Values from the calibration curve were used to convert fluores-
cent ratios to [Ca2þ]i. Final [Ca
2þ]i were calculated from the
background corrected 340/380 ratios using the Grynkiewicz
equation: [Ca2þ]i ¼ (Kd  Sf2/Sb2)  (R  Rmin)/(Rmax  R); where R
was the 340/380 ratio at any time; Rmax was the maximum mea-
sured ratio in saturating Ca2þ solution (39 lM free Ca2þ); Rmin
was the minimal measured ratio Ca2þ free solution; Sf2 was the
absolute value of the corrected 380-nm signal at Rmin; Sb2 was
the absolute value of the corrected 380-nm signal at Rmax; the Kd
value for Fura2 was 224 nM.
Western Blot Studies
Rats were deeply anesthetized under saturated isoflurane con-
ditions and then euthanized by decapitation. Brains were
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immediately removed and placed on glass surface cooled over
ice. The hippocampus was dissected out and flash frozen in liq-
uid nitrogen and stored at 80C until use. Frozen hippocampal
samples were added to 10 volumes of ice cold buffer containing:
50 mM Tris-HCL pH 7.5, 7 mM EGTA, 5 mM EDTA, 0.32 M su-
crose, 0.1 mM PMSF, and protease/phosphatase inhibitor cock-
tails (SigmaFast/PhosSTOP, Millipore Sigma, Burlington,
Massachusetts) and homogenized on ice using a motor driven
glass-teflon homogenizer (Glas-Col, Terre Haute, Indiana) at 900
rpm with 15 strokes. Samples underwent low speed (900  g,
4C) centrifugation to pellet nuclei. An aliquot of the superna-
tant (homogenate fraction) was saved and the remainder of
each sample underwent a second centrifugation at 10 000  g,
4C for 15 min to obtain a crude cytosol (supernatant) and P2
pellet fraction. Protein concentrations for all fractions were de-
termined by the Bradford micro-assay (Bio-Rad Laboratories,
Hercules, California) and read on a spectrophotometer
(NanoDrop 2000, Thermo Fisher Scientific, Waltham,
Massachusetts). Homogenate and cytosolic proteins (10–15 lG/
lane) were reduced in SDS sample buffer and resolved by dena-
turing gel electrophoresis (NuPage Novex SDS-PAGE, Invitrogen)
and then transferred to PVDF membrane for Western analysis.
For immunoblot analysis of medium to small proteins, samples
were resolved using 4%–12% Bis-Tris gels and transferred to
PVDF with 0.2-l pore size, while analysis of large M.W. proteins
were resolved using 7% Tris-Acetate gels and transferred to
PVDF with 0.4-l pore size. Following transfer, immunoblots
were incubated in tris-buffered saline (TBS) pH 7.4 containing
3% blotting-grade dry milk block (Bio-Rad) for 60 min on a rock-
ing platform at room temperature. Immunoblots were then in-
cubated in primary antibodies in TBS þ block for 1–24
h (overnight incubation was carried out at 4C) on a rocking
platform. The following antibodies were used: antiFKBP 12.6
(1:200, goat polyclonal, R&D Systems, Minneapolis, Minnesota),
antiRyR2 (phosphor S2808) (1:2 K, rabbit polyclonal, Abcam,
Cambridge, Massachusetts), antiRyR2 (1:1 K, rabbit polyclonal,
Alomone Labs, Jerusalem, Israel), antiPKA RII (1:2 K, goat poly-
clonal, EMD Millipore, Billerica, Massachusetts), antiIP3-1 (1:2 K,
rabbit polyclonal, EMD Millipore), antiPLC-c1 (1:1 K, clone 10:
mouse monoclonal, BD Biosciences), and antib-actin (1:20 K,
mouse monoclonal, Millipore Sigma). Immunoblots were
washed 4  10 min in TBS containing 0.05% Tween-20 (TBS-T)
(Bio-Rad), followed by a 60-min incubation with HRP-conjugated
secondary antibodies in TBS þ block (1:10 K; Santa Cruz
Biotechnology, Dallas, Texas). Immunoblots were washed 4  10
min in TBS-T followed by incubation in ECL detection reagent
(Amersham ECL Prime, GE Healthcare Biosciences, Pittsburg,
Pennsylvania) and exposed to x-ray film. Digital images of
Western films were obtained using high-resolution scanning
(Epson Expression 1680, Epson America Inc., Long Beach,
California) and underwent analysis using ImageJ analysis soft-
ware (ImageJ, NIH, public domain) to determine relative density
values. Values were normalized against antib-actin for loading
control.
Data Analysis
Data were analyzed, and graphs plotted using the SigmaPlot 14
software (SPSS Inc, Chicago, Illinois). Data were first examined
for normality using Shapiro-Wilk’s tests. Variables not normally
distributed were log transformed and normality confirmed on
the transformed data prior to analyses with t tests. Normally
distributed data were analyzed with independent t tests or a 1-
way analysis of variance (ANOVA) followed by post hoc Tukey’s
test wherever appropriate. In all cases, statistical significance
was indicated by *p < .05.
For [Ca2þ]i comparison between control and DFP-treated ani-
mals, a t-test was applied. For comparing the distributions of
[Ca2þ]i a Chi-square test was used. We used 5–9 animals for
each experimental condition. Dissociating the hippocampal sli-
ces routinely yielded 20–25 healthy, phase-bright neurons that
were used for the recordings. The means of each group of neu-
rons from each animal were used to evaluate results and con-
duct statistical analysis. Viable neurons included in the study
had a smooth surface and a pyramidal-like morphology with
processes. Nonviable neurons were swollen or circular and the
surface was uneven and irregular. Data from each animal were
pooled together in respective groups and ultimately represented
as total number of cells studied. For measuring changes in pro-
tein levels, relative densities for the specific protein bands were
measured, corrected for protein loading against b-actin and
then calculated as a % of control 6 SEM. Student’s t test was
used to compare optical densities between control and DFP rats.
For behavioral studies, we used a t test or 1-way ANOVA fol-
lowed by post hoc Tukey’s test wherever appropriate.
RESULTS
Chronic Hippocampal [Ca21]i Elevation in DFP Rats
Acutely isolated CA1 hippocampal neurons (Figure 2A) har-
vested from DFP rats manifested mean [Ca2þ]i of 348 6 11 nM
that was significantly higher than [Ca2þ]i of 181 6 8 nM in neu-
rons harvested from age-matched controls (*p < .01, t test, n ¼
8 rats, Figure 2B).
Analysis of the population distributions of [Ca2þ]i revealed
only 1% of age-matched control neurons exhibited [Ca2þ]i >500
nM, with the majority of neurons falling into the lower Ca2þ
concentration range. In contrast, approximately 40% neurons
isolated from DFP rats exhibited [Ca2þ]i between 250 and 500 nM
and approximately 10% neurons exhibited [Ca2þ]i > 500 nM indi-
cating a population shift towards higher Ca2þ concentration
range. This rightward shift in distribution of [Ca2þ]i levels in DFP
neurons was significantly different from control neurons (p <
.001, Chi-square test, n ¼ 150 neurons, Figure 2C).
Mechanism for Chronic Hippocampal [Ca21]i Elevations
in DFP Rats
Ratiometric recordings in the presence of effective concentra-
tions of inhibitors of voltage-gated Ca2þ channels (Nifedipine, 5
lM), a-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid
(AMPA) AMPA/kainate channels (6,7-dinitroquinoxaline-2,3-
dione (DNQX) DNQX, 10 lM) or other nonspecific cation chan-
nels Gadolinium chloride (GdCl3, 10 lM) did not produce a sig-
nificant decrease in [Ca2þ]i suggesting that these routes of
neuronal Ca2þ entry do not mediate chronic [Ca2þ]i elevations in
GWI rats. Application of NMDAR antagonist (MK-801, 10 lM)
produced a small but significant reduction in [Ca2þ]i suggesting
that NMDAR activity could be an important source of hippocam-
pal Ca2þ dysregulation in DFP neurons (*p < .05, t test, n ¼ 5 rats,
Figure 3A).
We next investigated the contribution of intracellular Ca2þ
release mechanisms towards protracted [Ca2þ]i increases in DFP
rats. Application of RyR antagonist dantrolene (50 lM) to hippo-
campal neurons isolated from DFP rats resulted in a significant
drop in [Ca2þ]i from 399 6 26 (no drug) to 240 6 11 nM (*p < .05, t
test, n ¼ 5 rats, Figure 3B). LEV has been shown to inhibit both
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RyR- and IP3R-activated CICR in hippocampal neurons
(Angehagen et al., 2003; Cataldi et al., 2004; Fukuyama et al., 2012;
Nagarkatti et al., 2008). Addition of LEV (100 lM) to hippocampal
neurons isolated from DFP rats reduced [Ca2þ]i to 251 6 19 nM
that was significantly lower than [Ca2þ]i in neurons isolated
from DFP rats (*p < .05, t test, n ¼ 5 rats, Figure 3B).
To further confirm involvement of CICR machinery in DFP-
induced Ca2þ elevations, we investigated the effect of in vivo
LEV treatment in DFP rats. CA1 neurons from LEV treated DFP
rats exhibited [Ca2þ]i of 270 6 21 nM that were significantly
lower than [Ca2þ]i in neurons isolated from DFP rats. LEV treat-
ment, however, did not restore [Ca2þ]i to baseline control levels
suggesting involvement of additional mechanisms in mainte-
nance of protracted [Ca2þ]i elevations in DFP rats (*p < .05, 1-
way ANOVA, n ¼ 5 rats, Figure 3C). Overall, an almost 60% re-
duction in [Ca2þ]i in the presence of dantrolene or LEV suggests
that IP3Rs and RyRs are significantly contributing to maintain-
ing the DFP-induced sustained Ca2þ elevations.
Estimations of Protein Levels of the Components of CICR
Machinery in DFP Rats
Western blot analysis of hippocampal homogenates were car-
ried out to evaluate possible alterations in the levels of CICR
protein targets in DFP rats. No significant changes in levels of
the CICR receptor proteins RyR-2 (0.82 6 0.13, 1.25 6 0.38) or
IP3-R (1.02 6 0.12, 0.996 0.08) or in the protein levels of signaling
enzymes PLCc1 (1.00 6 0.14, 1.13 6 0.04) or PKA (0.99 6 0.21, 1.03
6 0.24) were observed in DFP rats compared with control
(Figure 4).
We then measured protein levels of phosphorylated RyR2. A
small, but statistically insignificant increase in the p-RyR2 was
observed in DFP rats (1.37 6 0.35, 1.1 6 0.15; p ¼ .12, n ¼ 6 rats).
We next investigated expression of Calstabin2, also known as
FKBP12.6, which is a RyR2 stabilizer and keeps the receptor in a
closed-state. Western blot analysis with Calstabin2-specific an-
tibody staining revealed a significant downregulation in its ex-
pression in DFP rats. Levels for the hippocampal Calstabin2
binding protein showed a 42% decrease in DFP rats when com-
pared with control (0.87 6 0.069, 1.51 6 0.029). (*p < .05, t test, n
¼ 6 rats, Figure 4G).
Effect of CICR Inhibitor on Neurological Morbidities in
DFP Rats
Performance on sucrose preference test
Saline-treated control rats exhibited a strong preference for su-
crose water (78.1% 6 10.1%) which was not altered by LEV ther-
apy (75% 6 9%) suggesting that LEV treatment does not have an
effect on baseline sucrose preference in age-matched control
rats. In contrast, saline-treated DFP rats consumed significantly
low volume (44.2% 6 8.1%) of sucrose-laced water indicative of
anhedonia. LEV-treated DFP rats exhibited a greater preference
for sucrose water (68.8% 6 7.1%) which was significantly higher
than DFP rats but not significantly different from age-matched
control rats, suggesting that LEV therapy restored sucrose pref-
erence and improved anhedonia in DFP rats (1-way ANOVA, *p
< .05, n ¼ 8 rats, Figure 5A). No differences were observed be-
tween total fluid consumption and fluid consumed on right ver-
sus left-side amongst the different groups (p > .5, n ¼ 8,
Figure 5B).
Performance on FST
The FST is an effective test in evaluating the presence of a de-
spair; a common symptom of depression. Control rats treated
with saline exhibited an immobility time of 57.12 6 12.4 s while
age-matched control rats treated with LEV exhibited an immo-
bility time of 63.7 6 11 s, demonstrating that LEV alone has no
significant impact on mobility. DFP rats subjected to FST exhib-
ited an increased immobility time of 127.12 6 11.69 s indicative
of a despair-like state. In the presence of LEV therapy, there was
a reduction in the immobility time of DFP rats (81.08 6 6.97 s).
One-way ANOVA revealed significant differences amongst the
groups. Post hoc Tukey’s test revealed that DFP rats exhibited
significantly higher immobility time compared with age-
matched control rats. Further, LEV therapy did not alter baseline
behavior in control rats but significantly lowered immobility
time in DFP rats indicative of LEV’s potential antidepressant
Figure 2. Protracted hippocampal [Ca2þ]i following repeated, low-dose OP-DFP ex-
posure in rats. A, Pseudocolor ratiometric images of representative acutely isolated
hippocampal CA1 neurons from age-matched control and DFP rat. Control neurons
had bluish color that corresponds to lower Fura-2 ratio. DFP neurons had orange-
red color that corresponds to higher Fura-2 ratio. B, Bar graph comparing [Ca2þ]i in
control versus DFP neurons. CA1 hippocampal neurons acutely isolated at 3
months following repeated, low-dose DFP exposure exhibited an increased Fura-
2AM 340/380 ratios indicative of [Ca2þ]i that were significantly higher compared
with the calibrated [Ca2þ]i from age-matched control rats (data expressed as mean
6 SEM, *p < .05, t test, n ¼ 8 rats). C, Distribution of [Ca2þ]i levels for control and
DFP hippocampal neurons. CA1 neurons from age-matched control rats demon-
strated a normal distribution for [Ca2þ]i with approximately 95% of neurons exhib-
iting [Ca2þ]i <500 nM and only 2% neurons exhibiting very high [Ca
2þ]i. In contrast,
hippocampal neurons acutely isolated from DFP rats demonstrated a rightward
shift towards higher [Ca2þ]i with approximately 10% neurons exhibiting [Ca
2þ]i
>500 nM and approximately 50% neurons exhibiting [Ca2þ]i between 250 and 500
nM (p < .001, Chi-square test, n ¼ 150 neurons).
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effect. LEV therapy, however, was not able to restore DFP immo-
bility time to control values (n ¼ 7, *compared with CTLþSAL,
#compared with DFPþSAL, p < .05, Figure 6).
Performance on EPM
Measuring time spent and entries made by rats in the open ver-
sus closed arm of EPM reflects the anxiety state of rats and
allows for identification of anxiolytic effects following drug
treatment. Both the age-matched control rats treated with ei-
ther saline and LEV spent approximately 20% of time in the
open arms of EPM, which was not significantly different from
each other. In contrast, DFP rats spend only 5.3% 6 1.7% of time
in the open arm which was significantly different from age-
matched control rats. In the presence of LEV therapy, there was
a significant improvement in time spent in the open-arm of
EPM of DFP rats as evidenced by significantly greater open-arm
time (15.6% 6 2.7%) (*p < .05, 1-way ANOVA, n ¼ 8 rats,
Figure 7A). Improved EPM behavior in DFPþLEV rats were fur-
ther evidenced by significantly higher entries in the open-arm
compared with DFPþSAL rats. EPM performance by DFP rats in
the presence of LEV therapy matched the open-arm behavior
seen in age-matched control rats, indicative of LEV’s significant
anxiolytic effect (*p < .05, 1-way ANOVA, n ¼ 8 rats, Figure 7B).
We did not observe any significant differences in total arm
entries, distance moved, and speed between the various groups
suggesting no involvement of motor deficits in the EPM out-
comes (n ¼ 8, 1-way ANOVA, Figs. 7C–E).
Performance on novel object recognition
In the novel object recognition (NOR) choice phase, saline-
treated control rats spent 84.3% 6 8.7% of time with the novel
object which was significantly higher than time spent with fa-
miliar object (*p < .05, t test, n ¼ 6 rats, Figure 8A). LEV-treated
control rats also spent significantly higher time (80.2% 6 10%)
with the novel object compared with familiar object (*p < .05, t
test, n ¼ 7 rats, Figure 8B). This indicates that LEV therapy did
not alter baseline greater attraction for the novel object exhib-
ited under control conditions. However, saline-treated DFP rats
exhibited impaired recognition memory as evidenced by com-
parable time spent with both the familiar and the novel object.
Time spent with novel object was 53.3% 6 11% which was not
significantly different than time spent with familiar object (*p <
.05, t test, n ¼ 6 rats, Figure 8C). In contrast, DFP rats treated
with LEV spent a significantly greater amount of time exploring
the novel object (70.5% 6 14%) compared with familiar object (*p
< .05, t test, n ¼ 7 rats, Figure 8E).
To permit comparison across the groups, we calculated a
discrimination ratio that provided an index of time spent with
novel object as a fraction of total time spent exploring the 2
objects during the choice phase. As shown in Figure 8E, DFP rats
exhibited a discrimination ratio of 0.47 6 0.08 that was signifi-
cantly lower compared with the discrimination ratio of 0.86 6
0.05 obtained from age matched control rats indicative of im-
paired recognition memory. When treated with LEV, DFP rats
exhibited a discrimination ratio of 0.72 6 0.06 that was signifi-
cantly higher than DFP discrimination ratio indicating that LEV
therapy significantly improved NOR performance in DFP rats.
DFPþLEV discrimination ratio was also significantly lower than
age-matched control rats suggesting that LEV therapy could not
completely restore the object exploration behavior to the values
exhibited by control rats (*p < .05, 1-way ANOVA, n ¼ 7 rats,
Figure 8E). The distance traveled within the arena, total objects
exploration time, and the velocity in the choice phase were not
significantly different across groups suggesting that variable ob-
ject exploration or motor deficits did not affect the outcome of
NOR (p > .05, 1-way ANOVA, Figs. 8F–H).
DISCUSSION
Using an established OP DFP rat model (Phillips and Deshpande,
2016, 2018), our study has identified a unique molecular mecha-
nism that could possibly underlie the chronic expression of
neurological symptoms associated with GWI. A sustained in-
crease in intracellular Ca2þ levels was observed in the hippo-
campal neurons of DFP rats that had its origins in persistent
release of Ca2þ from intracellular stores. Western analysis
revealed a reduction in the levels of RyR stabilizing protein
Calstabin2. Further, pharmacological antagonism of RyR in iso-
lated hippocampal CA1 neurons from DFP rats significantly low-
ered the observed elevated Ca2þ and in vivo LEV therapy
improved GWI-like behavioral symptoms in DFP rats.
Neuronal Ca2þ influx is mediated by voltage-gated channels
and neurotransmitter ligand-gated channels (Hagenston and
Bading, 2011). Our studies showed that pharmacological
Figure 3. Mechanism for elevated hippocampal [Ca2þ]i in DFP rats. A, Effect of
inhibitors of Ca2þ influx pathways on [Ca2þ]i in DFP. Bath application of inhibi-
tors of voltage-gated Ca2þ channels (Nifedipine, 5 lM), AMPA/kainate channels
(DNQX, 10 lM) or other nonspecific cation channels (GdCl3, 10 lM) did not pro-
duce a significant decrease in [Ca2þ]i. Bath application of NMDA antagonist (MK-
801, 10 lM) produced a small but significant reduction in [Ca2þ]i (Data expressed
as mean 6 SEM, *p < .05, t test, n ¼ 5 rats). B, Effect of inhibitors of intracellular
Ca2þ release pathways on [Ca2þ]i in DFP neurons. Bath application of IP3/RyR an-
tagonist LEV (100 lM) or RyR antagonist dantrolene (Dant, 50 lM) produced
significant reductions in [Ca2þ]i. (Data expressed as mean 6 SEM, *p < .05, t test,
n ¼ 6 rats). C, Effect of LEV administration on [Ca2þ]i in DFP rats. Treatment with
LEV (50 mg/kg, i.p.) produced a significant reduction in [Ca2þ]i. compared with
DFP neurons but was significantly higher than age-matched control
neurons (CTL) (Data expressed as mean 6 SEM, *p < .05, 1-way ANOVA, Tukey’s
test, n ¼ 5 rats).
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inhibition of voltage-gated Ca2þ channels did not contribute to
the sustained Ca2þ increases in DFP neurons. However, blockade
of the NMDAR channel produced a small but significant drop in
DFP Ca2þ elevations. Increased glutamatergic neurotransmission
has been reported following repeated low-dose OP exposures
(Torres-Altoro et al., 2011) and in chronic neurodegenerative dis-
orders (Carvajal et al., 2016). Together these could lead to excito-
toxic activation of NMDAR leading to neuronal death in DFP rats.
Thus, NMDAR blockade could be neuroprotective and reduce
neuronal injury and ongoing cell-death in GWI. Unfortunately,
NMDAR antagonists have not been able to be safely translated for
therapy (Williams and Schatzberg, 2016). Our observations that
NMDAR blockade could not restore Ca2þ levels to baseline also
suggested that there could be mechanisms beyond Ca2þ influx
contributing to chronic Ca2þ dys-homeostasis in DFP rats.
Another major player in neuronal Ca2þ homeostasis is Ca2þ
release from intracellular stores that occurs via RyRs and IP3Rs
on the ER. Aberrant CICR has been implicated in many neurode-
generative diseases and neuropsychiatric conditions (Baker
et al., 2013; Kushnir et al., 2018; Popugaeva et al., 2017; Surmeier
et al., 2017; Tehse and Taghibiglou, 2018). In line with these
reports, our studies here show that RyR and RyR/IP3R antago-
nists significantly lowered elevated Ca2þ levels in DFP neurons.
The percent decrease in Ca2þ levels produced by CICR inhibition
Figure 4. Protein expression levels of the components of GWI hippocampal CICR machinery. Western immunoblots of hippocampal protein from DFP and age-matched
control (CTL) rats were stained for A, PKA RII; B, PLCc1; C, RyR2; D, IP3R1; E, phospho-RyR2; and F, Calstabin2. To adjust for sample loading, the blots were stained with
an antibody specific for the 42 kDa b-actin protein. G, Densitometric analyses of the Western blotting revealed no significant changes in proteins (A–E) but identified
significant reduction in the levels of Calstabin2 (F) compared with age-matched control (Data expressed as mean optical density 6 SEM, *p < .05, t test, n ¼ 6 rats).
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was higher than NMDAR antagonism suggesting that CICR
could be a dominant source of neuronal Ca2þ dysregulation in
DFP rats.
We next investigated how CICR could contribute to sus-
tained Ca2þ elevations following DFP exposures. Studies have
shown enhanced IP3R mediated Ca
2þ release under conditions
of hypoxia, stress, and seizures (Berridge and Taylor, 1988; Brini
et al., 2014; DeLorenzo et al., 2005; Hagenston and Bading, 2011).
Our Western blot studies did not reveal any significant change
in the protein expression of IP3R or PLCc in hippocampal homo-
genates from DFP rats. It is possible that IP3R activity could be
affected via mechanisms independent of changes in expression
of the receptor protein, and additional studies are needed to fur-
ther decipher involvement of IP3R machinery in this model.
There are 3 isoforms of RyR in the brain, all abundantly
expressed in the hippocampus (Hertle and Yeckel, 2007). RyR2
specifically is reported to be intricately involved in modulating
behavior (Abu-Omar et al., 2018; Kushnir et al., 2018) and has
been implicated in stress-induced cognitive dysfunction (Liu
et al., 2012). Further, pharmacological blockade of RyRs afforded
neuroprotection in a rat model of OP intoxication (Deshpande
et al., 2016). In this study, we did not observe significant changes
in the protein expression of RyR2 between age-matched control
and DFP rats. Posttranslational remodeling of brain and cardiac
RyR2 including phosphorylation, oxidation, and nitrosylation
has been reported in animal models of PTSD, Alzheimer’s, and
heart failure (Lacampagne et al., 2017; Lehnart et al., 2008; Liu
et al., 2012; Marx et al., 2000). We probed for p-RYR2 expression
in hippocampal homogenates from control and DFP rats and ob-
served a small but statistically insignificant increase in the p-
RYR2 expression in DFP rats. In our attempts to further probe
the molecular mechanisms underlying sustained Ca2þ eleva-
tions in GWI, we investigated expression of Calstabin2, also
known as FKBP12.6, in DFP rats. Calstabin2 is a critical
regulatory subunit of the RyR2 macromolecular complex (Yuan
et al., 2016). It selectively binds to and stabilizes RyR2 in a
closed-state (Zalk et al., 2015). We observed that hippocampal
homogenates from DFP rats exhibited significant depletions in
Calstabin2 expression. It has been reported that under stress-
induced conditions, posttranslational modification of RyR2
results in dissociation of Calstabin2 rendering RyR2 “leaky” and
releasing Ca2þ from ER (Lehnart et al., 2008; Liu et al., 2012; Yuan
et al., 2016). Thus, “leaky” neuronal RyR could also underlie GWI
neuropathology. Additional studies are needed to experimen-
tally confirm leaky RyRs in our dissociated neuronal prepara-
tion. Our data that hippocampal neurons isolated from LEV-
treated DFP-rats display significantly lower Ca2þ levels supports
the involvement of RyR in GWI-like phenotype.
We next investigated whether blockade of CICR mechanism
would also provide relief from the symptoms of GWI-like neuro-
psychiatric abnormalities. Several studies have demonstrated
that LEV (Keppra), an FDA-approved antiepileptic drug,
decreases CICR (Angehagen et al., 2003; Cataldi et al., 2005;
Fukuyama et al., 2012; Nagarkatti et al., 2008). LEV is also
reported to produce significant memory improvement in
Alzheimer’s’ patients (Musaeus et al., 2017) and improved neu-
robehavioral outcomes after TBI (Zou et al., 2013). These neuro-
logical conditions are also associated Ca2þ dysregulation
(Surmeier et al., 2017; Tehse and Taghibiglou, 2018). We there-
fore investigated if LEV could be repurposed for the treatment of
GWI-like neurological symptoms. In agreement with previous
studies, LEV did not affect baseline behavior in naı¨ve rats
(Barker-Haliski et al., 2016; Gower et al., 2003). In contrast, LEV
significantly improved symptoms of depression, anxiety, and
cognitive deficits in DFP rats. However, LEV was not able to
completely restore all the DFP behavioral morbidities to control
baseline performance.
A critical question remains if LEV therapy is also able to re-
verse the underlying molecular changes that are responsible for
elevated Ca2þ levels in DFP neurons. Our observation that
in vitro or in vivo LEV couldn’t completely restore elevated Ca2þ
levels or GWI-like behavioral symptoms to baseline suggests
that there could be additional mechanisms contributing to the
maintenance of elevated Ca2þ levels and GWI phenotype.
Indeed, many other mechanisms have been purported for GWI-
like neuropsychiatric symptoms in OP-based rodent models in-
cluding neuroinflammation (Koo et al., 2018; Parihar et al., 2013),
oxidative stress (Shetty et al., 2017), mitochondrial dysfunction
Figure 5. Effect of LEV therapy on sucrose preference in DFP rats. Sucrose prefer-
ence test: A, Bar graph shows significantly lower sucrose consumption in
DFPþSAL rats compared with age-matched CTL groups indicative of significant
anhedonia. DFPþLEV rats were significantly higher than on DFPþSAL but not
significantly different than CTLþSAL group indicative of restoration of sucrose
preference in DFP rats following LEV therapy. CTLþSAL and CTLþLEV groups
were not different from each other. B, No differences were observed in the total
fluid volume consumed between the various groups. (Data expressed as mean 6
SEM, *p < .05, 1-way ANOVA, Tukey’s test, n ¼ 8 rats; *compared with CTLþSAL).
Figure 6. Effect of LEV therapy on immobility time in DFP rats. FST: Graph shows
increased immobility time in DFPþSAL rats compared with CTLþSAL rats indi-
cating that DFP treatment produced increased behavioral despair. A decreased
immobility time in DFPþLEV compared with DFPþSAL rats during the FST, indi-
cated improvement in behavioral despair score. DFPþLEV immobility time was
significantly higher than CTLþLEV group suggesting that LEV therapy could not
restore despair-like symptoms to baseline values. No significant differences in
immobility times were noted between CTLþSAL and CTLþLEV groups (Data
expressed as mean 6 SEM, *#p < .05, 1-way ANOVA, Tukey’s test, n ¼ 7 rats;
*compared with CTLþSAL and #compared with DFPþSAL).
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(Shetty et al., 2017), and increased glutamatergic transmission
(Torres-Altoro et al., 2011). Furthermore, LEV has several biologi-
cal effects in addition to blocking RyR and IP3R activity, includ-
ing inhibition of n-type calcium channels, the modulation of
GABA and glycine receptors, and binding to SV2A protein
(reviewed in De Smedt et al., 2007). These pleiotropic
mechanisms could be contributing to the in vivo actions of LEV
in addition to its effects on CICR observed here. Our study pro-
vides a possible molecular mechanism for GWI-like neurologi-
cal morbidities in DFP rats and suggests that agents such as LEV
could prove to be promising therapeutic option for managing
GWI neurological symptoms.
Figure 7. Anxiolytic effects of LEV therapy in DFP rats. EPM: Bar graph shows significantly lower time spent in the open-arm (A) and significantly higher closed-arm
and less open-arm entries (B) by DFP rats indicative of anxiety-like condition and a significant anxiolytic effect of LEV therapy in DFP rats. LEV alone did not alter base-
line EPM exploratory behavior while DFPþLEV rats were not significantly different than age-matched control rats. Bar graph shows no significant changes between to-
tal arm entries (C), distance moved (D), and velocity (E) between the age-matched control and DFP rats treated with saline or LEV. (Data expressed as mean 6 SEM, *p <
.05, 1-way ANOVA, Tukey’s test, n ¼ 8 rats; *compared with CTLþSAL).
Figure 8. LEV therapy improves NOR memory in DFP rats. NOR: Bar charts compare percentages of time spent exploring the familiar object (FAM) and the novel object
(NOV) in age-matched saline (SAL, A), LEV (B), DFP (C), and DFP þ LEV (D) rats. Note the comparable time spent by DFP rats interacting with FAM and NOV objects (Data
expressed as mean 6 SEM, *p < .05, t test, n ¼ 7 rats). E, Discrimination ratio comparisons between various groups. DFPþLEV discrimination ratio was significantly
higher than DFPþSAL group but was significantly lower than CTLþLEV group suggesting that while LEV therapy improves NOR memory in DFP rats, it does not restore
NOR memory to baseline values. No significant differences in discrimination ratios were noted between CTLþSAL and CTLþLEV groups (Data expressed as mean 6
SEM, *#p < .05, 1-way ANOVA, Tukey’s test, n ¼ 7 rats; *compared with CTLþSAL and #compared with DFPþSAL). Bar graphs compares the total distance traveled (F),
the total object exploration time (G), and the velocity of movement (H) between the age-matched control and DFP rats treated with saline or LEV. Note that the overall
motor activity was similar between the various groups.
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